Masimo Stock Price, News & Analysis

Masimo Corporation (NASDAQ: MASI) is a global medical technology company in the electromechanical and electrotherapeutic apparatus manufacturing industry. According to company disclosures, Masimo develops and produces a wide array of monitoring technologies used in healthcare settings, with a focus on noninvasive patient monitoring, sensors, patient monitors, and automation and connectivity solutions. The company states that its mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications.

Masimo reports that its business has historically included healthcare and non-healthcare segments. The healthcare segment has been described as a key revenue driver, developing, manufacturing, and marketing noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices, and consumer health products. The non-healthcare segment has included a consumer audio business that developed, manufactured, marketed, sold, and licensed premium and luxury audio sound products and related integration technologies.

In a Form 8-K filed on September 23, 2025, Masimo disclosed that it completed the sale of its consumer audio business, held through Viper Holdings Corporation (Sound United), to Harman International Industries, Incorporated. The transaction transferred all of Masimo’s equity interests in Sound United to the buyer for cash consideration, meaning the consumer audio operations described as part of the non-healthcare segment were divested as of that date. Subsequent financial reporting referenced in later filings and press releases focuses on the continuing operations of Masimo’s healthcare business.

Core technologies and clinical focus

Masimo highlights Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry as a foundational technology. The company states that this pulse oximetry technology, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo reports that Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry technology at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing.

In addition to pulse oximetry, Masimo describes its portfolio as including monitoring technologies, innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Company communications emphasize that these innovations are intended to empower clinicians to transform patient care, particularly through noninvasive monitoring and hospital connectivity.

Business model and segments

Based on company descriptions and filings, Masimo’s business model centers on developing, manufacturing, and marketing medical monitoring technologies and related products. Revenue is associated with the sale of monitoring technologies, sensors, patient monitors, and connectivity and automation solutions, as well as, historically, the sale and licensing of consumer audio products before the divestiture of Sound United.

Masimo has described two primary segments in prior disclosures:

• Healthcare segment – Identified as the key revenue driver, this segment develops, manufactures, and markets noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices, and consumer health products.
• Non-healthcare segment – Previously included the consumer audio business, which developed, manufactured, marketed, sold, and licensed premium and luxury audio sound products and related integration technologies. As disclosed in the September 23, 2025 Form 8-K, this consumer audio business was sold to Harman International Industries.

Following the completion of the Sound United transaction, Masimo’s continuing operations, as referenced in its third quarter 2025 results, relate to the healthcare business. The company also discusses strategic realignment initiatives and business transition costs in its non-GAAP financial measure explanations, reflecting efforts to focus on core healthcare operations.

Industry position and clinical evidence

Masimo repeatedly cites clinical evidence as central to its value proposition. The company notes that Masimo SET® pulse oximetry has been evaluated in over 100 independent and objective studies and that it is estimated to be used on more than 200 million patients annually worldwide. Company press releases highlight that Masimo SET® is the primary pulse oximetry technology at all 10 top U.S. hospitals in the 2025 Newsweek World’s Best Hospitals listing.

In October 2025, Masimo announced results from a feasibility study within the INSPIRE trial, conducted at the Medical University of South Carolina, examining the performance of Masimo SET® pulse oximetry among critically ill adult ICU patients across a spectrum of skin tones. The exploratory analysis reported that Masimo SET® performed accurately among patients of all skin tones, including those with low perfusion requiring vasopressors, and that no occult hypoxemic events were observed in the analyzed dataset. These findings were described as consistent with previous laboratory and retrospective studies that demonstrated accuracy on patients with both dark and light skin tones.

Legal and intellectual property context

Masimo’s disclosures and news releases describe extensive intellectual property activity, particularly in relation to Apple Inc. The company has been engaged in various legal proceedings against Apple since January 2020, including federal court cases, U.S. Patent and Trademark Office proceedings, and a U.S. International Trade Commission proceeding. In November 2025, Masimo issued a statement on a California jury verdict confirming the validity of a Masimo patent, finding infringement by Apple, and awarding damages. The company characterizes these efforts as part of its commitment to protecting innovations and intellectual property that underpin its medical technologies.

In its non-GAAP financial measure explanations, Masimo notes that it excludes litigation-related expenses and settlements associated with these Apple-related proceedings from certain non-GAAP metrics, describing these expenses as unique in nature and not indicative of ongoing operating performance.

Financial reporting and guidance

Masimo provides regular financial updates through press releases and Form 8-K filings. These communications discuss GAAP and non-GAAP revenue, operating income, earnings per diluted share, and constant currency revenue growth, along with explanations of non-GAAP adjustments such as acquisition-related amortization, business transition costs, litigation expenses, realized and unrealized gains or losses, financing-related adjustments, and tax impacts of non-GAAP items.

The company also issues preliminary financial results and long-range targets, and it hosts conference calls and investor days to discuss its strategy, growth pillars, and financial outlook. In these contexts, Masimo emphasizes its focus on its healthcare business, operating efficiency initiatives, and long-term growth in patient monitoring and related technologies.

Corporate structure and regulatory filings

Masimo Corporation is incorporated in Delaware and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-33642. SEC filings, including multiple Form 8-Ks in 2025, document financial results, guidance updates, board changes, and the completion of the Sound United divestiture. These filings provide detailed information on Masimo’s financial performance, non-GAAP measures, and significant corporate events.

FAQs about Masimo Corporation (MASI)